228 related articles for article (PubMed ID: 11669473)
1. Characterization of high-affinity [3H]TBZOH binding to the human platelet vesicular monoamine transporter.
Zucker M; Weizman A; Rehavi M
Life Sci; 2001 Sep; 69(19):2311-7. PubMed ID: 11669473
[TBL] [Abstract][Full Text] [Related]
2. Effects of nerve growth factor on dihydrotetrabenazine binding to PC12 cells.
Adamson CR; Emley TE; Herbig LJ; Near JA
Neurochem Int; 1997; 30(4-5):411-5. PubMed ID: 9106255
[TBL] [Abstract][Full Text] [Related]
3. Decreased platelet vesicular monoamine transporter density in habitual smokers.
Schwartz K; Weizman A; Rehavi M
Eur Neuropsychopharmacol; 2005 Mar; 15(2):235-8. PubMed ID: 15695071
[TBL] [Abstract][Full Text] [Related]
4. Regulation of rat brain vesicular monoamine transporter by chronic treatment with ovarian hormones.
Rehavi M; Goldin M; Roz N; Weizman A
Brain Res Mol Brain Res; 1998 Jun; 57(1):31-7. PubMed ID: 9630494
[TBL] [Abstract][Full Text] [Related]
5. Autoradiographic distribution of the eye monoaminergic synaptic vesicles.
Denis P; Nordmann JP; Scherman D; Saraux H; Rostène W
Ophthalmic Res; 1994; 26(4):232-9. PubMed ID: 7808734
[TBL] [Abstract][Full Text] [Related]
6. Decreased platelet vesicular monoamine transporter density in children and adolescents with attention deficit/hyperactivity disorder.
Toren P; Rehavi M; Luski A; Roz N; Laor N; Lask M; Weizman A
Eur Neuropsychopharmacol; 2005 Mar; 15(2):159-62. PubMed ID: 15695060
[TBL] [Abstract][Full Text] [Related]
7. Elevated platelet vesicular monoamine transporter density in untreated patients diagnosed with major depression.
Zucker M; Aviv A; Shelef A; Weizman A; Rehavi M
Psychiatry Res; 2002 Nov; 112(3):251-6. PubMed ID: 12450634
[TBL] [Abstract][Full Text] [Related]
8. Increased platelet vesicular monoamine transporter density in adult schizophrenia patients.
Zucker M; Valevski A; Weizman A; Rehavi M
Eur Neuropsychopharmacol; 2002 Aug; 12(4):343-7. PubMed ID: 12126874
[TBL] [Abstract][Full Text] [Related]
9. Lobeline displaces [3H]dihydrotetrabenazine binding and releases [3H]dopamine from rat striatal synaptic vesicles: comparison with d-amphetamine.
Teng L; Crooks PA; Dwoskin LP
J Neurochem; 1998 Jul; 71(1):258-65. PubMed ID: 9648873
[TBL] [Abstract][Full Text] [Related]
10. Decreased limbic vesicular monoamine transporter 2 in a genetic rat model of depression.
Schwartz K; Yadid G; Weizman A; Rehavi M
Brain Res; 2003 Mar; 965(1-2):174-9. PubMed ID: 12591135
[TBL] [Abstract][Full Text] [Related]
11. High-efficiency expression and characterization of the synaptic-vesicle monoamine transporter from baculovirus-infected insect cells.
Sievert MK; Thiriot DS; Edwards RH; Ruoho AE
Biochem J; 1998 Mar; 330 ( Pt 2)(Pt 2):959-66. PubMed ID: 9480916
[TBL] [Abstract][Full Text] [Related]
12. Reserpine affects differentially the density of the vesicular monoamine transporter and dihydrotetrabenazine binding sites.
Naudon L; Raisman-Vozari R; Edwards RH; Leroux-Nicollet I; Peter D; Liu Y; Costentin J
Eur J Neurosci; 1996 Apr; 8(4):842-6. PubMed ID: 9081637
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the subregional distributions of the monoamine vesicular transporter and dopamine uptake complex in the rat striatum and changes during aging.
Leroux-Nicollet I; Costentin J
J Neural Transm Gen Sect; 1994; 97(2):93-106. PubMed ID: 7873127
[TBL] [Abstract][Full Text] [Related]
14. Transient expression of the vesicular monoamine transporter during development in the rat thalamus and cortex.
Leroux-Nicollet I; Costentin J
Neurosci Lett; 1998 Jun; 248(3):167-70. PubMed ID: 9654335
[TBL] [Abstract][Full Text] [Related]
15. Chronic clozapine, but not haloperidol, treatment affects rat brain vesicular monoamine transporter 2.
Rehavi M; Roz N; Weizman A
Eur Neuropsychopharmacol; 2002 Jun; 12(3):261-8. PubMed ID: 12007678
[TBL] [Abstract][Full Text] [Related]
16. Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters.
Miller DK; Crooks PA; Zheng G; Grinevich VP; Norrholm SD; Dwoskin LP
J Pharmacol Exp Ther; 2004 Sep; 310(3):1035-45. PubMed ID: 15121762
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo studies of benzisoquinoline ligands for the brain synaptic vesicle monoamine transporter.
Lee LC; Vander Borght T; Sherman PS; Frey KA; Kilbourn MR
J Med Chem; 1996 Jan; 39(1):191-6. PubMed ID: 8568807
[TBL] [Abstract][Full Text] [Related]
18. Chimeric vesicular monoamine transporters identify structural domains that influence substrate affinity and sensitivity to tetrabenazine.
Peter D; Vu T; Edwards RH
J Biol Chem; 1996 Feb; 271(6):2979-86. PubMed ID: 8621690
[TBL] [Abstract][Full Text] [Related]
19. Reserpine or chronic paroxetine treatments do not modify the vesicular monoamine transporter 2 expression in serotonin-containing regions of the rat brain.
Vilpoux C; Leroux-Nicollet I; Naudon L; Raisman-Vozari R; Costentin J
Neuropharmacology; 2000 Apr; 39(6):1075-82. PubMed ID: 10727718
[TBL] [Abstract][Full Text] [Related]
20. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice.
Kilbourn MR; Kuszpit K; Sherman P
Synapse; 2000 Mar; 35(4):250-5. PubMed ID: 10657034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
